AMERICAN swimming champion and mental health advocate Michael Phelps has been appointed to the board of Medibio Limited, an ASX-listed company which has developed an "effective, objective test to help with the diagnosis of depression, chronic stress and other mental health disorders".
Phelps retired from competitive swimming last year and since then has actively sought to raise awareness of mental health issues.
Medibio's system is based on more than 15 years of research at the University of Western Australia, and uses patented (and patent pending) circadian, sleep and autonomic system biomarkers to objectively quantify and characterise mental illness.
Phelps has used the technology to analyse his own personal datasets, having personally suffered from his mental health challenges since he was a teenager.
Medibio ceo Jack Cosentino welcomed Phelps as a director, saying the appointment "validates the great need for objective mental health diagnosis that we offer through our industry-leading technology".
Phelps' agent Peter Carlisle, influential in the Olympic and sports movement in his own right, will serve as an alternate board member for Medibio Limited.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jun 17
